期刊
LIVER INTERNATIONAL
卷 31, 期 -, 页码 151-160出版社
WILEY
DOI: 10.1111/j.1478-3231.2010.02395.x
关键词
angiogenesis inhibitors; clinical trial; hepatocellular carcinoma; targeted therapies
资金
- AAREC (Association d'Aide a la Recherche et l'Enseignement en Cancerologie)
The approval of sorafenib as the standard of care (SOC) for advanced hepatocellular carcinoma (HCC) fostered interest to further evaluate several other targeted therapies and extend the positioning of sorafenib alone and in combination with other drugs and local therapies at earlier stages and in an adjuvant setting. This review highlights current research using targeted therapies in HCC. Information for this review was compiled by searching PubMed and MEDLINE databases for articles published until September 2010. Several small molecules and humanized antibodies with anti-angiogenic and antiproliferative properties are currently being investigated in preclinical and/or clinical trials. Results are awaited from these clinical trials and offer promise for extending the current treatment options in HCC. Currently published data suggest that substantial progress may be achieved in the treatment of patients with HCC in the next 10 years.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据